Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...
Please provide your email address to receive an email when new articles are posted on . AD onset in infants was significantly delayed with high vs. low dietary diversity during pregnancy. There was a ...
WESTLAKE VILLAGE, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA ...
As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an ...
The point prevalence of atopic dermatitis was highest in those aged 0 to 5 years among children and adolescents and in those aged 18 to 59 years among adults. The estimated global point prevalence of ...
If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...
Repeated-measures modeling found no consistent links between active atopic dermatitis and BMI, blood pressure, lipid profiles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results